Vreeland v. Metagenomi names the company, unnamed officers and directors under Section 11. The court partly denied dismissal on March 24, 2026; the S-1 shows who signed.
Metagenomi filed a $250,000,000 shelf and signed a $75,000,000 at-the-market sales agreement with Jefferies LLC, which can earn up to 3.0% commission. The filing does not state the company's cash balance, and sales can start only after the registration statement is declared effective.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $39.0 million, plus short-term investments of $81.6 million, $120.7 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Metagenomi Therapeutics
Is there a class action against Metagenomi Therapeutics?
Our latest story on this, dated Aug 10, 2026: "Metagenomi's IPO class action over Moderna collaboration disclosures moves into discovery". The story links the filing or release it is based on. Read the story.
When did Metagenomi Therapeutics go public?
Our latest story on this, dated Aug 10, 2026: "Metagenomi's IPO class action over Moderna collaboration disclosures moves into discovery". The story links the filing or release it is based on. Read the story.
Has Metagenomi Therapeutics raised money recently?
Our latest story on this, dated Mar 17, 2025: "Metagenomi files $250,000,000 shelf and $75,000,000 at-the-market program". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Metagenomi Therapeutics?
Metagenomi Therapeutics, Inc. trades under the ticker MGX on NASDAQ.
Where is Metagenomi Therapeutics listed?
Metagenomi Therapeutics, Inc. is listed on NASDAQ.
What is the SEC CIK of Metagenomi Therapeutics?
The SEC Central Index Key (CIK) for Metagenomi Therapeutics, Inc. is 1785279. Its filings are on SEC EDGAR.
How many shares does Metagenomi Therapeutics have outstanding?
37,777,105 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-10.
Which country or territory is Metagenomi Therapeutics listed under?
Our directory records Metagenomi Therapeutics, Inc. under United States.
What does Metagenomi Therapeutics do?
Our directory classifies Metagenomi Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Metagenomi Therapeutics?
The ISIN recorded for Metagenomi Therapeutics, Inc. is US59102M1045.
Does aibio.space cover Metagenomi Therapeutics?
aibio.space lists Metagenomi Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
What was Metagenomi Therapeutics's revenue last year?
$25.2 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Metagenomi Therapeutics profitable?
Metagenomi Therapeutics, Inc. reported a net loss of $87.9 million for the fiscal year ended Dec 31, 2025, and used $88.9 million of cash in operations, per its annual report to the SEC.
How much does Metagenomi Therapeutics spend on research and development?
$94.4 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Metagenomi Therapeutics have?
$120.7 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Investor discussion: Metagenomi Therapeutics
Members talk about Metagenomi Therapeutics (MGX). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Metagenomi Therapeutics, newest first. Each line links the filing it comes from.
Distress
Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:MGX on TradingView.
SEC filings and registration
SEC name
Metagenomi Therapeutics, Inc.
CIK
1785279
Industry (SIC)
Biological Products, (No Diagnostic Substances) (2836)
US tickers
MGX (Nasdaq)
Fiscal year ends
December 31
Filer category
<br>Emerging growth company
Business address
5959 HORTON STREET, EMERYVILLE, CA, 94608
Phone
(510) 871-4880
Shares outstanding
37,777,105 as of 2026-08-06 (10-Q filed 2026-08-10)
Former names
Metagenomi, Inc.; Metagenomi Technologies, LLC
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Metagenomi Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker MGX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio